Neuroone Medical Technologies Corp (NMTC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Neuroone Medical Technologies Corp stock (NMTC) is currently trading at $0.77. Neuroone Medical Technologies Corp PS ratio (Price-to-Sales) is 3.33. Analyst consensus price target for NMTC is $2.03. WallStSmart rates NMTC as Sell.
- NMTC PE ratio analysis and historical PE chart
- NMTC PS ratio (Price-to-Sales) history and trend
- NMTC intrinsic value — DCF, Graham Number, EPV models
- NMTC stock price prediction 2025 2026 2027 2028 2029 2030
- NMTC fair value vs current price
- NMTC insider transactions and insider buying
- Is NMTC undervalued or overvalued?
- Neuroone Medical Technologies Corp financial analysis — revenue, earnings, cash flow
- NMTC Piotroski F-Score and Altman Z-Score
- NMTC analyst price target and Smart Rating
Neuroone Medical Technologies Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Neuroone Medical Technologies Corp (NMTC) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Neuroone Medical Technologies Corp (NMTC) Key Strengths (0)
Supporting Valuation Data
Neuroone Medical Technologies Corp (NMTC) Areas to Watch (8)
Company is destroying shareholder value
Losing money on operations
Revenue declining -11.70%, a shrinking business
Company is losing money with a negative profit margin
Very expensive at 6.1x book value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Revenue is fairly priced at 3.33x sales
Neuroone Medical Technologies Corp (NMTC) Detailed Analysis Report
Overall Assessment
This company scores 15/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 0 register as strengths (avg 0/10) while 8 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (3.33), Price/Book (6.08) suggest expensive pricing. Growth concerns include Revenue Growth at -11.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -146.30%, Operating Margin at -59.00%, Profit Margin at -58.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -146.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -11.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NMTC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NMTC's Price-to-Sales ratio of 3.33x sits near its historical average of 3.31x (43th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 8% below its historical high of 3.63x set in Mar 2026, and 15% above its historical low of 2.89x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~2.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Neuroone Medical Technologies Corp (NMTC) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Neuroone Medical Technologies Corp is in a turnaround phase, with management focused on restoring profitability. Revenue reached 12M with 12% decline year-over-year. The company is currently unprofitable, posting a -58.3% profit margin.
Key Findings
Debt-to-equity ratio of 0.02 indicates a conservative balance sheet with 4M in cash.
Revenue contracted 12% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -58.3% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Neuroone Medical Technologies Corp.
Bottom Line
Neuroone Medical Technologies Corp is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Neuroone Medical Technologies Corp(NMTC)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
NeuroOne Medical Technologies Corporation is a medical technology company. The company is headquartered in Eden Prairie, Minnesota.